

## Beaumont Laboratory

Dearborn – Farmington Hills – Grosse Pointe – Royal Oak – Taylor – Trenton – Troy – Wayne

### ALGORITHMS FOR REFLEX TESTS

#### CLINICAL PATHOLOGY

##### ABO Grouping:

- If patient appears to be group A or AB with unexpectedly positive reverse typing, then ...
  - Reflex testing: special antigen typing for A1 antigen, and antibody identification
  - Process followed for group AB patients also.
- If patient appears to be group B with unexpectedly positive reverse typing, then...
  - Reflex testing: antibody identification.

##### Acid Elution: (Royal Oak)

- The Hematology Laboratory performs the test when the Flow Cytometry Laboratory is closed. Specimen is then forwarded to Flow Cytometry for the Fetal RBC Assay.

##### AFB Culture:

- Includes molecular testing M.tb complex and rifampin resistance as indicated on sputum and tracheal aspirates ONLY.

##### Amniotic fluid AFP:

- If elevated AFP MoM or there is a specific clinical history, sample sent to an outside lab for repeat AFP and if necessary, acetylcholinesterase testing.

##### Amniotic fluid algorithm:

- If the Lamellar Body Count (LBC) is consistent with fetal lung immaturity, sample is sent to Mayo Medical Labs for an L/S-PG. If the LBC indicates maturity, no more testing performed.

##### Anti-Nuclear Antibody (ANA) evaluation:

- Run ANA screen by immunofluorescence
- If greater than cut-off, immunofluorescence microscopy performed - pattern and titer reported.

##### Anti-Nuclear Antibody (ANA) evaluation with reflex:

- Run ANA screen by immunofluorescence
- If result is positive, report titer and pattern AND reflex to specific autoantibodies for SSA, SSB, Smith, RNP and dsDNA.

##### Antibody Identification:

- If a new antibody specificity is identified, then...
  - Reflex testing: Special Antigen Typing of patient's RBCs for each specificity (may result in multiple charges).
- If autologous control is positive during antibody identification, then...
  - Reflex testing: Direct Antiglobulin Test x1 (DAT X3 polyspecific, monospecific IgG and C3d done if poly is positive).
- If prenatal patient has or has had clinically significant antibody identified, then...
  - Reflex testing: Antibody Titer q 3-4 weeks. If multiple clinically significant antibodies are present, then a titer is performed for each specificity resulting in multiple charges.
- If antibody activity includes a broadly reactive cold or warm antibody interfering with determination and identification of alloantibodies or crossmatches, then...
  - Reflex testing may include: Adsorptions, Pretreat RBC w/ Enzymes and/or Pretreat Serum by Dilution and/or Pretreat Serum by Diff, Red Cell Adsorptions and Antibody Identification, antigen

***Printed copies of this document need to be confirmed with online version to verify that it is up-to-date before use.***

typing of the patient. Multiple charges may be generated for each sample depending upon complexity of the serological problem.

- If an Antibody Identification is ordered and the patient has no previous history of antibody, then...
  - Indirect Coombs (Antibody Screen) is performed first.
- If an Antibody Titer is ordered, and the patient has not had antibody identification performed within the last month, then...
  - Antibody Identification is performed first.

#### Antibody Screening (Indirect Coombs):

- If patient has no previous history of a positive antibody screen, then...
  - Reflex testing: Antibody Identification. Multiple antibody identification panels may be performed in order to elicit antibody specificity.
- If patient has previous history of a positive antibody screen, and ...
  1. Time elapsed since the last antibody identification is
    - greater than 1 month for an obstetrical patient, or
    - greater than 3 months for a non-obstetrical patient, OR
  2. Reactivity occurs with RBCs known to lack the corresponding antigen, OR
  3. Reactivity has increased in strength since the last antibody screen, OR
  4. Patient has a previous history of a WAA (warm auto-antibody) that is currently reactive in the antibody screen OR
  5. Patient is incompatible when crossmatched with antigen negative RBCs, then...
    - Reflex testing: Antibody Identification. Multiple antibody panels may be performed in order to elicit antibody specificity(ies)
- If patient has or previously has had a positive antibody screen (not due to Rh Immune Globulin administration) then...
  - Reflex testing: two (2) RBCs are crossmatched in addition to crossmatch orders.
- If obstetrical patient has history of or current clinically significant antibody, then...
  - Reflex testing: cord blood survey consisting of Direct Antiglobulin Test, Typing ABO, Typing RHO (D), Special Antigen Typing. Multiple charges for Special Antigen Typing if mother has multiple clinically significant antibodies.

#### Blood Culture:

- Rapid blood culture identification with the BCID2 will be performed on the first positive blood culture per admission. Subsequent positive blood cultures will not be tested with BCID2 unless a new organism or morphology is seen on the Gram stain.

#### Bone Marrow:

- Ancillary testing, including special stains, immunoperoxidase stains, flow cytometry, cytogenetics, FISH and molecular testing will be performed for diagnostic purposes, on bone marrows and other hematopoietic specimens, as determined necessary by the pathologist to render a diagnosis.
- Cytogenetics, FISH and molecular testing will be performed for prognostic and treatment purposes, based on DMT guidelines (Appendix I).

#### *Clostridium difficile* CDH/Toxin NAA testing:

- In cases where GDH is negative and Toxin A/B is positive, NAA testing is performed.

#### Complete Blood Count (CBC):

- If results are abnormal and meet criteria for requiring pathologist review, add differential. The slides, instrument printout and lab printout are saved for pathologist review.

#### Complete Blood Count with Differential (CBC/diff):

- If results are abnormal and meet criteria for requiring pathologist review, the slides, instrument print out, and lab print out are saved for pathologist review.
- If sickle cells are found on a differential, a sickle cell screen is performed if no previous history.
- If suspect microorganisms are seen on smear, refer to Microbiology for confirmation.

***Printed copies of this document need to be confirmed with online version to verify that it is up-to-date before use.***

## Comprehensive Drug analysis:

- All drugs found on immunoassay screen (amphetamine, cocaine, cannabinoids, barbiturates, benzodiazepines, opiates, methadone, PCP, fentanyl, oxycodone) are confirmed by an alternate method

## Crossmatching:

- If patient has clinically significant antibody(ies), then...
  - Reflex testing: Unit Antigen Screen with antisera. Multiple charges generated (# of units tested x number of antigens tested for)...
- If patient with a previous history of clinically significant antibody has incompatible crossmatches with units known to lack corresponding antigen(s), then...
  - Reflex testing: Antibody Identification
- If patient has incompatible crossmatches due to broadly reactive warm or cold auto or allo antibody, then...
  - Reflex testing: Unit Antigen Screen with patient sera, unit antigen screen with reagent anti-sera, phenotypically similar matched units or least incompatible. Multiple charges will be generated equal to number of units tested to locate compatible or least incompatible.
- If patient has a history of Sickle Cell Anemia/Thalassemia then...
  - Units will be confirmed Hemoglobin S negative (additional charge per unit), and antigen negative (C, E, Kell) per patient antigen typing. Multiple charges generated (# of units tested x number of antigens tested for)

## Cryoglobulins:

- If a positive cryoglobulin is detected, cryoglobulin characterization and quantitation will be performed automatically the first time the cryoglobulin is detected. Characterization will not be repeated for a given patient unless it is clinically appropriate.

## Cryptococcal Antigen Test (CSF only):

- Reflex to include a culture (if not ordered) - College of American Pathologists guideline

## CSF cell count and differential:

- All CSF specimens with WBC counts within the normal range ( $\leq 5$  WBC/mcL) will have a CSF scan differential performed. RBCs, PMNs and mononuclear cells will be reported if present.
- If the CSF WBC count is above the normal range ( $> 5$  WBC/mcL), a differential will be performed.
- If results are abnormal and meet criteria for requiring pathologist review, the slides and lab print out are saved for pathologist review.
- If suspect microorganisms are seen on the smear, refer to Microbiology for confirmation.

## Direct Antiglobulin Test:

- If Direct Antiglobulin Test is positive for IgG, and patient is baby of mother with clinically significant antibody, then...
  - Reflex testing: Antibody Identification on eluate from baby's RBCs.
- If Direct Antiglobulin Test is positive on post transfusion reaction specimen, then...
  - Reflex testing: Antibody Identification on eluate from patient's RBCs.
- If a Direct Antiglobulin Test is ordered on a patient  $> 4$  months of age, then...
  - DAT is performed using polyspecific AHG. If positive then reflex test: 2 additional DATs IgG and C3 (monospecific).
  - If Direct Antiglobulin Test is positive within two weeks of transfusion, then...
    - Reflex Testing: Transfusion Reaction Evaluation if deemed necessary by pathologist

## Drugs of Abuse screen with confirmation (amphetamine, cocaine, cannabinoids, barbiturates, benzodiazepines, opiates, methadone, PCP, fentanyl, oxycodone):

- All positive results are confirmed by an alternate method.

## DRVVT (screen and confirm):

- A dRVVT screen is performed. If screen is abnormal, a confirmation test is performed on the patient and a control. Normalized ratio of screening test to confirmation test is calculated and reported.

***Printed copies of this document need to be confirmed with online version to verify that it is up-to-date before use.***

## Fetal Cell Screening:

- If post-partum mother is Rh(D) negative and baby is Rh(D) positive, then...
  - Reflex testing: Fetal Cell Screen
- If the fetal cell screen is positive, mother or baby is weak D positive, OR baby's Rh type cannot be determined (e.g. no specimen, invalid Rh testing results), then...
  - Reflex testing: Fetal RBC Assay (FMH) ordered by Blood Bank.

## Fluid cell count and differential:

- Body fluid differentials will be performed when the WBC count is >5 mL.
- If results are abnormal and meet criteria for requiring pathologist review, the slides and lab print out are saved for pathologist review.
- If suspect microorganisms are seen on the smear, refer to Microbiology for confirmation.

## Group A Strep Screen:

- If positive, no additional testing is performed unless specifically requested
- If negative, reflex to Group A Strep by Nucleic Acid Amplification for ages < 16 years.

## Group B Strep Screen (*Streptococcus agalactiae*):

- A vaginal/rectal screen reflex to include susceptibility testing.

## HBsAg:

- Confirmed when result meets criteria of >1.00 - <50.00. If >50, then not required.

## HCV antibody testing for inpatient "source" cases:

- All positives are tested for HCV RNA Quantitation by PCR

## Hepatitis C Screening (Effective: 3/1/2022)

- Hepatitis C virus (HCV) quantitative nucleic acid amplification test will be automatically added to all positive/reactive hepatitis C virus antibody tests.

## Hemoglobinopathy evaluation:

- Run chromatography (Bio Rad Variant)
- If abnormal hemoglobin detected, run electrophoresis

## Hexagonal Phase Phospholipid (screen and confirm):

- A hexagonal screen is performed. If the screen is abnormal, a confirmation test is performed on the patient. The difference between the screen and confirmation is calculated and reported.

## HIV antigen/antibody testing:

- HIV 1/2 antibody and p24 HIV-1 antigen test used as initial screen. If positive, additional testing performed using BioRad Geenius.
- If Geenius is negative or equivocal, sample(s) sent to outside lab for HIV-1 RNA and if appropriate HIV-2 DNA/RNA testing.

HLA: HLA antibody identification ordered and performed when the HLA (cytotoxic) antibody screen is positive.

## HLA B27:

- If flow result is in equivocal range, report as "equivocal" and refer for Class 1 typing for disease association.

IgG subclasses: Total IgG included

## Inhibitor coagulation screen:

- PT and PTT performed. At Royal Oak, if the PTT is prolonged, a thrombin time is performed to rule out drug effect. Farmington Hills, Royal Oak and Troy perform heparin absorption as needed. If PT is prolonged or the PTT is prolonged without evidence of heparin, then 1:1 mixing studies are performed both

***Printed copies of this document need to be confirmed with online version to verify that it is up-to-date before use.***

immediately and after 120 min incubation at 37°C. Additional testing and/or pathologist interpretation is performed as needed.

### Lactic Acid

- When an initial plasma lactic acid has a result > 2.0 mmol/L (i.e. 2.1 or greater), a STAT redraw order for a 2<sup>nd</sup> plasma lactic acid will occur automatically. This will be scheduled for 2 hours after the initial draw. The reflex will apply to emergency center and in-patients; it will not apply to any outpatient requests.

### Lupus Anticoagulant:

- If this is ordered it reflexes to “Coagulation consult for anti-phospholipid antibody.”

### Lyme Antibody:

- All positive or equivocal results will be sent out for Immunoblot testing.

### Molecular Genotyping:

- Molecular Genotyping (send out test) will be performed (additional charge generated):
  - When a patient has 3 or more Alloantibodies OR
  - Patient has Sickle Cell/Thalassemia OR
  - Patient is a Warm Autoantibody patient OR
  - Patient being treated for Multiple Myeloma (Daratumumab)

### Peripheral Smears with Microorganisms:

- Reflexed to Microbiology for further evaluation.

### Protein C:

- Protein C activity is performed. If abnormal and the patient is not on Coumadin, it is verified with a protein C antigen.

### Protein S:

- Protein S activity is performed. If abnormal and the patient is not on Coumadin, it is verified with a protein S free and total antigen.

### Serum monoclonal gammopathy evaluation:

- Run SPE and complete immunofixation
- If new abnormality or monoclonal obscured by other proteins, one or more immunoglobulin quantitations performed.
- Immunoglobulin quantitations also performed at discretion of pathologist (e.g. hypogammaglobulinemia).

### Serum protein electrophoresis: all patients

- If a significant abnormality is detected on serum protein electrophoresis and the pathologist or clinical chemist determines that an immunofixation is appropriate, an immunofixation is performed.

### Sickle Cell:

- If sickle cell screen is positive, Hemoglobinopathy evaluation is reflexed.

### Syphilis Screening (Reverse Algorithm)

- Initial screening for total antibody (IgG and IgM) specific for *Treponema Pallidum* using a chemiluminescent immunoassay is performed.
- If total antibody is reactive, an RPR will be performed.
- If total antibody and RPR results are discordant (i.e. total antibody reactive, RPR nonreactive), a TP-PA test will be performed.

Smear Blood Parasite → Includes Malaria antigen screen when indicated

**Printed copies of this document need to be confirmed with online version to verify that it is up-to-date before use.**

TSH with reflex to free T4:

- TSH performed
- If TSH falls outside specified limits, a free T4 is automatically performed.

Urinalysis:

- Dipstick testing is performed; if positive result encountered (other than urobilinogen), automated and/or manual microscopy is performed.

Urine protein electrophoresis:

- Run UPE and kappa/lambda immunofixation
- Run complete immunofixation at Pathologist's discretion or if new abnormality

RPR:

- All positives tested by TP-PA (Treponema pallidum particle agglutination) – Effective 01/03/2017

Yeast – Antimicrobial sensitivity testing (AST) will be performed on all yeast recovered from blood cultures.

## ANATOMIC PATHOLOGY

In the Anatomic Pathology laboratory, pathologists use their judgement to order and examine additional studies on submitted specimens if they deem them medically necessary to render a diagnosis. In these situations, pathologists are acting in the capacity of a consultant in the care of the patient. This includes but is not limited to ordering special stains, decalcification of tissue, immunoperoxidase stains, microbiology cultures on tissue specimens, electron microscopy, and flow cytometry on certain tumors if indicated.

The Anatomic Pathology reflex test list includes tests that Beaumont Laboratory performs if a specimen meets the reflex criteria listed and tests that are often useful for the diagnosis and prognosis of the patient. Treating providers may decline the reflex testing by indicating that on the laboratory requisition or by contacting Beaumont Laboratory's Customer Service Department.

BCR/ABL1 for t(9;22)(q34;q11.2) detection

- When a BCR/ABL1 Dual Color Dual Fusion Translocation probe produces an atypical signal pattern (1R1G1F in >23% of nuclei) indicating the arginosuccinate synthetase (ASS) gene on chromosome 9q34 may be deleted, reflex testing to the BCR/ABL1 + 9q34 Tri-Color Dual Fusion probe should be performed to determine if there is an ASS gene deletion present.

Estrogen and Progesterone Receptor Status (IHC)

- Performed on all newly diagnosed invasive and recurrent/metastatic breast cancers to assess responsiveness to endocrine therapy

Epidermal Growth Factor Receptor EGFR (PCR) Mutation Analysis (Effective: 3/1/2022)

- Performed on all lung resections (wedge resection, segmentectomy, lobectomy and pneumonectomy) positive for non-small cell lung carcinoma (NSCLC) tumors

Fluorescence *in situ* hybridization (FISH) Panels

- All FISH panels are performed according to the DMT guidelines (Appendix I).

Her2-Status (IHC and FISH)

- Performed on all newly diagnosed and recurrent invasive breast cancers, and metastatic tumors, to guide the decision to pursue Her2-targeted therapy.
  - If the Her2 test result on a core biopsy specimen of a primary tumor is **negative** and the tumor is grade 3; or a small amount of tumor in the core biopsy; or resection specimen contains high-grade carcinoma morphologically distinct from that of the core specimen; then repeat testing on an excisional specimen
  - If the Her2 test result on a core biopsy specimen of a primary tumor is **positive** and the tumor is histologic grade 1 that is of the following histologic types: infiltrating ductal or lobular and is ER- and

**Printed copies of this document need to be confirmed with online version to verify that it is up-to-date before use.**

PgR-positive, or tubular, or mucinous, or cribriform, or adenoid cystic carcinoma, then repeat testing on an excisional specimen

- Performed on all newly diagnosed gastric, gastroesophageal junction adenocarcinomas and their recurrences/metastases
- Performed on all newly diagnosed distant metastases of colorectal carcinoma.

IDH1 (Isocitrate Dehydrogenase) (IHC)

- Performed on all infiltrating gliomas for diagnostic and prognostic purpose

Ki67 (IHC) (Effective: 4/5/2022)

- Performed on all newly diagnosed breast invasive carcinomas and breast carcinoma recurrences.

MGMT (O6-Methylguanine-DNA Methyltransferase (**MGMT**)) Methylation Status

- Biomarker in pediatric and adult patients with glioblastoma, for diagnostic and therapy guiding purpose

Mismatch Repair Analysis (IHC)

- Performed on all newly resected colorectal carcinomas and endometrial carcinoma as a screen for Lynch syndrome
- Performed on any metastatic carcinoma (from any primary organ site) for possible immunotherapy.

Aggressive B-Cell Lymphoma Panel

- Performed according to aggressive B-cell lymphoma FISH diagnostic algorithm (DMT guidelines).

PDL-1 (Clone 22C3)

- Performed on all newly diagnosed metastatic non-small cell lung carcinoma (NSCLC subtypes: adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, large cell neuroendocrine carcinoma, NSCLC favor squamous cell/adenocarcinoma, or NSCLC-NOS).
- Performed on all metastatic carcinoma in which the possibility of a NSCLC cannot be entirely excluded.

p16

- Immunohistochemistry (IHC) testing performed on all newly diagnosed head and neck squamous carcinomas arising in the oropharynx (Base of tongue and tonsils)
- IHC testing performed on squamous carcinoma presenting as a lymph node metastasis of unknown primary site

---

## Appendix I – Amended DMT Guidelines to include Reflex NGS Testing

*Printed copies of this document need to be confirmed with online version to verify that it is up-to-date before use.*

**NGS TESTING FOR MYELOID MALIGNANCY**

Effective immediately, the hematopathology department will reflex all bone marrows with a new diagnosis of acute myeloid leukemia or a new diagnosis of myelodysplasia for a myeloid panel by next generation sequencing (NGS). Additional testing will continue to follow the DMT guidelines below.

Due to the required turn-around time for FLT3 this test will continue to be sent out as a single gene test to University of Michigan, in addition to the myeloid panel by NGS. Repeat testing for positive markers will also be performed as individual gene tests.

<p>B Lymphoblastic Leukemia/Lymphoma</p>	<ul style="list-style-type: none"> <li>• Karyotype</li> <li>• ALL FISH Panel [4,10 trisomy, t(9;22), 11q23 rearrangement, t(12;21), t(1;19), IGH/IL3 for t(5;14), iAMP21, ABL1, ABL2, PDGFRB per Children’s Oncology Group protocol]</li> <li>• RT-PCR for BCR-ABL1</li> <li>• Send out for Phil-like ALL FISH Panel testing (MAYO), at ordering physician request only</li> </ul>
<p>Acute Myeloid Leukemia, including evolving AML</p>	<ul style="list-style-type: none"> <li>• Karyotype</li> <li>• Limited AML FISH Panel [CBFB gene rearrangement for inv16/t(16;16), p53, t(15;17), MLL, t(9;22), NUP98] on all</li> </ul>

*Printed copies of this document need to be confirmed with online version to verify that it is up-to-date before use.*

	<ul style="list-style-type: none"> <li>Expanded FISH panel upon request to also include t(8;21) and 3q26 rearrangement</li> <li>Next Generation Sequencing - Myeloid Panel</li> <li>FLT3</li> </ul>
Myelodysplastic Syndrome	<ul style="list-style-type: none"> <li>Karyotype</li> <li>Next Generation Sequencing - Myeloid Panel</li> <li>FISH only upon request or at discretion of pathologist or if traditional karyotype obtained &lt;20 metaphases [MDS FISH Panel: trisomy 8,del(20q),monosomy 5/del(5q),monosomy 7/del(7q),3q26 rearrangement, monosomy 13/del(13q), MLL,p53]</li> </ul>
Myeloproliferative Neoplasms	<ul style="list-style-type: none"> <li>Karyotype</li> <li>FISH or RT-PCR for BCR-ABL1</li> <li>JAK2 V617F, if negative CALR, MPL (ET and MF) and JAK2 Exon 12 (PV)</li> </ul>
Myelodysplastic/Myeloproliferative Neoplasms including Chronic Myelomonocytic Leukemia	<ul style="list-style-type: none"> <li>Karyotype</li> <li>FISH or RT-PCR for BCR-ABL1</li> <li>JAK2 V617F, if negative CALR and MPL</li> <li>Eosinophilia FISH Panel [FIP1L1/PDGFRB, PDGFRB, FGFR1 and JAK2 rearrangements]</li> <li>MDS FISH only upon request or at discretion of pathologist or if traditional karyotype obtained &lt;20 metaphases [MDS FISH Panel: trisomy 8,del(20q),monosomy 5/del(5q),monosomy 7/del(7q),3q26 rearrangement, monosomy 13/del(13q), MLL,p53]</li> </ul>
Eosinophilia associated with myeloid/lymphoid neoplasms	<ul style="list-style-type: none"> <li>Eosinophilia FISH Panel [FIP1L1/PDGFRB, PDGFRB, FGFR1 and JAK2 rearrangements]</li> </ul>
Plasma Cell Myeloma	<ul style="list-style-type: none"> <li>Karyotype</li> <li>Myeloma FISH Panel [CDKN2C/CKS1B for chromosome 1q rearrangement, CEP3/7 for hyperdiploidy, monosomy 13/del(13q), p53, IGH/CCND1 with reflex to IGH/FGFR3, IGH/MAF, and IGH/MAFB]</li> </ul>
Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma	<ul style="list-style-type: none"> <li>CLL FISH Panel [MYB/CEP6, trisomy 12, p53, ATM,monosomy 13/del(13q), IGH/CCND1]</li> <li>Karyotype</li> </ul>
Diffuse Large B-cell Lymphoma	<ul style="list-style-type: none"> <li>FISH for double hit lymphoma all cases [MYC and IGH/MYC; Reflex to BCL2 and BCL6 if MYC rearranged]</li> <li>Karyotype optional</li> </ul>
Burkitt Lymphoma	<ul style="list-style-type: none"> <li>[FISH for IGH/MYC with reflex to IGK/MYC and IGL/MYC]</li> </ul>
Hairy Cell Leukemia	<ul style="list-style-type: none"> <li>BRAF V600E (send out)</li> </ul>

**Printed copies of this document need to be confirmed with online version to verify that it is up-to-date before use.**

<b>NGS Test</b>	Lymphoplasmacytic Lymphoma	<ul style="list-style-type: none"> <li>• MYD88 L265P</li> <li>• CXCR4 at request of ordering physician for patient’s being considered for ibrutinib</li> </ul>
	Gastric Malt Lymphoma	<ul style="list-style-type: none"> <li>• H. pylori testing (also should be performed in gastric DLBCL)</li> <li>• If positive for H. pylori; FISH for t(11;18) will be performed</li> </ul>
	T-cell leukemia/lymphoma including T-cell Prolymphocytic Leukemia	<ul style="list-style-type: none"> <li>• Karyotype</li> <li>• T-cell leukemia/lymphoma FISH Panel [TCL1 (14q32),TCRAD (14q11), TCRB (7q434), and TLX3 (5q32) rearrangements; chromosome 8 abnormalities; del(9p)]</li> </ul>
	Peripheral T-cell Lymphoma and Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders	<ul style="list-style-type: none"> <li>• FISH for DUSP22 if ALK negative ALCL consideration (paraffin only)</li> </ul>
	Other lymphomas	<ul style="list-style-type: none"> <li>• Additional cytogenetic and molecular testing is useful under certain circumstances and will be performed at discretion of pathologist; nothing routinely performed or required</li> <li>• NHL FISH Panel (IGH/CCND1, IGH/BCL2, MALT1, MYC, BCL6)</li> </ul>

**Information:**

The Myeloid Neoplasm NGS Panel (42 genes) is designed for sequencing both DNA and RNA for the detection of single nucleotide variants (SNV), insertion/deletion mutations (indels), gene copy number changes (CNV), and gene fusions in the following genes:

ABL1, ABL2, ASXL1, BCR, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MLL, MYD88, MPL, NPM1, NRAS, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SRSF2, SMC3, STAG2, TET2, TP53, WT1, ZRSR2

**Synonyms:**

TSO500, TruSight Oncology 500, next generation sequencing, NGS, myeloid panel

**Test Code:**

Soft code-5 character: MMYLD  
 EPIC code: LAB7971

**CPT Code(s):**

81450, G0452

*Printed copies of this document need to be confirmed with online version to verify that it is up-to-date before use.*

**Specimen Collection Criteria:****Bone Marrow:**

- 1.0 mL bone marrow aspirate in a Lavender-top EDTA tube. (Minimum: 0.5 mL).
- The specimen must be accompanied by a completed requisition and must contain the patient name, date of birth, collection date, ordering physician, clinical diagnosis, and source of specimen.

**Specimen Preparation for Courier Transport:**

- Transport all bone marrow at room temperature (20-26°C or 68-78.8°F).

**Rejection Criteria**

- Specimens collected in heparin (Green-top), clot tubes (Red-top), ACD anti-coagulant tubes, or SST tubes.
- Improper labeling or inadequate information.
- Poor quality and/or quantity of extracted genomic DNA.
- Frozen specimens.
- Unlabeled tubes or samples.

Testing will be cancelled on specimens meeting the above criteria with client notification. Under certain circumstances (i.e., lack of alternative specimens), testing may proceed with approval from the medical director or designee.

**Performed**

Once or twice per week, dependent upon test volume. Results available in 10-15 business days.

**Reference Range**

No variants detected or likely benign variants detected.

**Test Methodology**

RNA, DNA or both are isolated from the sample and quantified. Recovered nucleic acid extracts are prepared for sequencing with the Illumina TruSight Oncology 500 library preparation kit and sequenced on the Illumina NextSeq instrument with the Illumina TruSight Oncology 500 sequencing kit. Analysis is performed using PierianDx Clinical Genomics Workspace (CGW) software.

A personalized interpretive report is generated for each sample that lists the variants detected in each gene, classifies these based on a standardized classification scheme for somatic variants, and provides interpretative comments for each variant of known significance.

***Printed copies of this document need to be confirmed with online version to verify that it is up-to-date before use.***

## Interpretation

Test results should be interpreted in the context of clinical findings, tumor sampling, and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory director.

---

**Date submitted: May 11, 2021**

**Submitted by: Ann Marie Blenc, MD, System Medical Director, Hematopathology  
Mitual Amin, MD, System Medical Director, Anatomic Pathology  
Susan Daraiseh, PhD, Technical Director, Molecular Pathology**

*Printed copies of this document need to be confirmed with online version to verify that it is up-to-date before use.*